Atransferrinemia

Atransferrinemia
Synonyms	Familial atransferrinemia
Pronounce	N/A
Field	Hematology
Symptoms	Anemia, iron overload
Complications	Heart failure, liver damage, arthritis
Onset	N/A
Duration	N/A
Types	N/A
Causes	Mutations in the transferrin (TF) gene
Risks	N/A
Diagnosis	Transferrin levels, blood tests, genetic testing, physical examination
Differential diagnosis	N/A
Prevention	N/A
Treatment	Apotransferrin therapy
Medication	None; iron therapy is contraindicated
Prognosis	Manageable with appropriate treatment
Frequency	Extremely rare (fewer than 15 cases documented)
Deaths	Rare; often due to complications if untreated

Atransferrinemia is a rare genetic disorder that falls under inborn errors of metal metabolism. It is caused by a deficiency or absence of transferrin, a plasma protein responsible for transporting iron in the bloodstream. A lack of transferrin disrupts iron delivery to cells, leading to anemia and hemosiderosis (iron overload) in organs such as the heart, liver, and pancreas.

Clinical Features

The primary symptoms of atransferrinemia include:

• Severe microcytic anemia (small, pale red blood cells)
• Iron deposition in organs, leading to:
  • Heart failure
  • Liver damage
  • Arthritis
  • Pancreatic dysfunction
• Recurrent infections due to weakened immune response.

The anemia is both microcytic and hypochromic, with red blood cells unable to function properly due to insufficient iron delivery.

Pathophysiology

The transferrin protein, encoded by the TF gene, is crucial for transporting iron to the reticuloendothelial system for erythropoiesis. In atransferrinemia, the absence of transferrin leads to:

• An inability to deliver iron for red blood cell production.
• Excess iron accumulating in the heart, liver, pancreas, and joints, causing tissue damage.
• Elevated serum ferritin levels as the body attempts to bind excess free iron.

Genetics

Atransferrinemia is inherited in an autosomal recessive manner, meaning a person must inherit defective copies of the TF gene from both parents. Mutations in the TF gene impair the production or function of transferrin. Genetic testing can confirm mutations in affected individuals.

Diagnosis

Diagnosing atransferrinemia involves:

• Blood tests showing severe anemia with microcytic and hypochromic characteristics.
• Measurement of transferrin levels, which are typically absent or very low.
• Genetic testing to identify mutations in the TF gene.
• Imaging studies to assess iron overload in organs.

Differential diagnosis includes other conditions that cause microcytic anemia, such as iron-deficiency anemia and thalassemia.

Treatment

The cornerstone of treatment is:

• Apotransferrin therapy: This replaces the missing transferrin protein and restores proper iron transport.
• Management of iron overload:
  • Iron chelation therapy may be required to prevent organ damage.
• Avoidance of iron therapy: Oral or intravenous iron supplements are contraindicated, as they exacerbate iron overload without correcting anemia.

Prognosis

With early diagnosis and appropriate treatment, the prognosis for atransferrinemia is favorable. Left untreated, complications such as cardiac failure and liver cirrhosis can be life-threatening.

Epidemiology

Atransferrinemia is an extremely rare condition, with fewer than 15 documented cases worldwide. Most cases are identified in consanguineous families due to the autosomal recessive inheritance pattern.

Related Conditions

• Hypotransferrinemia
• Hemochromatosis
• Microcytic anemia

See Also

• Iron metabolism
• Transferrin receptor
• Inborn errors of metabolism

External Links

Classification	ICD-10: E88.0 OMIM: 209300 DiseasesDB: 29538
External resources